eIF4E-IN-6

• UNSPSC Description:

  eIF4E-IN-6(compound 4b) is a GMP analogs synthesized to targeteIF4Eand restrain its binding to cap mRNA.eIF4E-IN-6shows cell cytotoxicity against Caco-2, HepG-2,and MCF-7 cells, withIC50values of 31, 27, and 21 μM, respectively[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/eif4e-in-6.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NC(NC(C2=CC=CC=C2)=O)=NC3=C1[N+](CC4=CC=CC=C4)=CN3C5OC(COP(NNC6=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C6)(O[Na])=O)C7C5OC(C)(C)O7.[Br-]

• Molecular Weight:

  880.53

• References & Citations:

  [1]Attia RT, et al. Newly Synthesized Anticancer Purine Derivatives Inhibiting p-EIF4E Using Surface-Modified Lipid Nanovesicles. ACS Omega. 2023;8(41):37864-37881. Published 2023 Oct 6.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported